BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Gilead Sciences, Inc. 

333 Lakeside Drive

Foster City  California  94404  U.S.A.
Phone: 800-GILEAD-5 or 650-574-3000 Fax: 650-522-5800


SEARCH JOBS




Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need.The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.


 Key Statistics


Email:
Ownership: Public

Web Site: Gilead
Employees: 4,000
Symbol: GILD
 



Industry
Biotechnology






 Company News
Japan’s Ministry Of Health, Labour And Welfare Approves Gilead (GILD)’s Sovaldi (Sofosbuvir) For The Treatment Of Genotype 2 Chronic Hepatitis C 3/26/2015 9:20:03 AM
Gilead (GILD)'s $600 Million Man 3/25/2015 12:24:01 PM
Gilead (GILD) Release: Multiple Provinces Align To Provide Public Funding For Harvoni, The First Single Tablet Regimen For The Treatment Of Genotype 1 Chronic Hepatitis C Virus Infection 3/24/2015 2:22:56 PM
Gilead (GILD) Warns After Nine Hepatitis Patients Taking Heart Drug Develop Condition, One Dies From Cardiac Arrest 3/23/2015 6:03:21 AM
Hetero Received Generic Sofosbuvir (Gilead (GILD)'s Sovaldi) Approval From Drug Controller General Of India (DCGI) 3/12/2015 11:38:47 AM
Gilead (GILD) To Present At The Barclays Global Healthcare Conference On Wednesday, March 11 3/11/2015 10:20:05 AM
Gilead (GILD) To Present At The Cowen and Company 35th Annual Health Care Conference On Tuesday, March 3 3/3/2015 11:58:04 AM
Gilead (GILD) Announces Phase 3 Results For Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF) 2/27/2015 10:40:52 AM
Gilead (GILD) Announces SVR12 Rates From Phase III Study Evaluating Harvoni For The Treatment Of Chronic Hepatitis C In Patients Co-Infected With HIV 2/27/2015 6:18:07 AM
Gilead (GILD)'s Harvoni Achieves 96% Cure Rate in Patients With Hepatitis C and HIV 2/27/2015 6:16:45 AM
12345678910...